News & Publications for:

Mark Sands

Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss

Posted on October 20, 2016

Benitez BA, Cairns NJ, Schmidt RE, Morris JC, Norton JB, Cruchaga C, Sands MS. Acta Neuropathol Commun. 2015 Nov 26;3:73. PMID: 26610600 Read More

Posted in: HPAN, Lysosome, Neurodegeneration, Neurogenetics, Publications Faculty: , , ,

An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis

Posted on October 20, 2014

Macauley S, Wong AMS, Shyng C, Augner DP, Dearborn JT, Yewande P, Roberts MS, Fowler SC, Cooper JD, Watterson DM, Sands MS; The Journal of Neuroscience, Volume 34 (39), September 2014, p13077-13082 Read More

Posted in: HPAN, Neurodegeneration, Publications Faculty:

Astrocytosis in infantile neuronal ceroid lipofuscinosis: Friend or foe?

Posted on October 20, 2014

Shyng C, Sands MS; Biochemical Society Transactions, Volume 42, p1282-1285 Read More

Posted in: HPAN, Neurodegeneration, Publications Faculty:

Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice

Posted on September 24, 2013

Heldermon CD, Qin EY, Ohlemiller KK, Herzog ED, Brown JR, Vogler C, Hou W, Orrock JL, Crawford BE, Sands MS; (2013) Gene Therapy, 20 (9), pp. 913-921. Read More

Posted in: Neurogenetics, Publications Faculty: ,